Mittwoch, 24.06.2026, Calendar Week 26, 175. day of the year, 190 days remaining until EoY.

Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.

Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

FR0012127173

Filter zurücksetzen

Do you already know our new terminal view? Click here.

FIGI: BBG008891XD6

OSE

OSE Immunotherapeutics SA

GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH

NAME

OSE Immunotherapeutics SA

ISIN

FR0012127173

TICKER

OSE

MIC

XPAR

REUTERS

OSE.PA

BLOOMBERG

OSE FP

Mi., 02.07.2025 OSE Immunotherapeutics

Newsfeed

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics met à jour l’information sur les procédures en cours | OSE Immunotherapeutics SA

OSE Immunotherapeutics Publishes Letter to Shareholders | OSE Immunotherapeutics SA

OSE Immunotherapeutics provides an update on ongoing proceedings | OSE Immunotherapeutics SA

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules | OSE Immunotherapeutics SA

ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025 | OSE Immunotherapeutics SA

UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

Ose Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025 | OSE Immunotherapeutics SA

OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025 | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab | OSE Immunotherapeutics SA

Mise à disposition du Document d’Enregistrement Universel incluant le Rapport Financier 2024 | OSE Immunotherapeutics SA

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025 | OSE Immunotherapeutics SA

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 | OSE Immunotherapeutics SA

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update | OSE Immunotherapeutics SA

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer | OSE Immunotherapeutics SA

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO | OSE Immunotherapeutics SA

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy | OSE Immunotherapeutics SA

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer | OSE Immunotherapeutics SA

Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO | OSE Immunotherapeutics SA

OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Strengthens Leadership and Executive Committee | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis | OSE Immunotherapeutics SA

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis | OSE Immunotherapeutics SA

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies | OSE Immunotherapeutics SA

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21) | OSE Immunotherapeutics SA

OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth | OSE Immunotherapeutics SA

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse | OSE Immunotherapeutics SA

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Provides Business and Corporate Update | OSE Immunotherapeutics SA

Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 19 juin 2024 | OSE Immunotherapeutics SA

Mise à disposition du Document d’Enregistrement Universel incluant le Rapport Financier 2023 | OSE Immunotherapeutics SA